Otsuka (OTCMKTS:OTSKY) Shares Gap Down – What’s Next?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares gapped down prior to trading on Tuesday . The stock had previously closed at $33.12, but opened at $31.4492. Otsuka shares last traded at $32.09, with a volume of 3,057 shares traded.

Analyst Ratings Changes

A number of brokerages have commented on OTSKY. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Otsuka currently has a consensus rating of “Hold”.

Otsuka Price Performance

The company has a market cap of $34.27 billion and a P/E ratio of 13.46. The firm has a 50 day moving average of $34.95 and a 200-day moving average of $32.17. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, equities research analysts predict that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 EPS for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.